Stocks making the biggest moves after hours: Adobe, Ulta Beauty, Lennar & more

Check out the companies making headlines in after-hours trading. Ulta Beauty — Ulta shares dropped 8% after the beauty products retailer reported weak earnings results . For its fourth quarter, Ulta posted earnings of $8.01 per share, falling short of the $8.03 per share that analysts polled by LSEG were expecting. The retailer’s revenue of $3.90 billion came out ahead of the $3.80 billion expected. Adobe — The software giant saw shares tumble nearly 7%. CEO Shantanu Narayen said that he would step down from his post after a successor has been named. Narayen will remain as chair of the company’s board. He has been Adobe’s CEO since 2007. The news overshadowed first-quarter beats on the top and bottom lines. Lennar — The homebuilder dropped 2% in the after-hours session, after Lennar reported a second quarterly earnings miss in a row. The company reported earnings of 93 cents per share on revenue of $6.62 billion, falling short of the 96 cents per share and $6.88 billion that was expected by analysts polled by LSEG. Rubrik — The data security and cloud stock popped 2% after posting fourth-quarter adjusted earnings of 4 cents per share, while analysts polled by LSEG had anticipated a loss of 11 cents. The company’s $378 million revenue also exceeded expectations of $342 million. Rubrik also sees its first-quarter revenue coming in between $365 million to $367 million, above the consensus forecast of $351 million. Sentinel One — The cybersecurity stock fell nearly 3%. SentinelOne issued a weak outlook for first-quarter adjusted earnings, calling for a range of 1 cent to 2 cents per share, missing the LSEG consensus of 5 cents per share. In the fourth quarter, SentinelOne posted earnings that narrowly topped estimates, but revenue of $271 million was in line with expectations. Insulet — The maker of continuous glucose monitoring devices is recalling certain batches of its Omnipod 5 pods. The company said some batches have a small tear in the internal tubing that can result in patients not receiving the intended dosage of insulin. Several users were hospitalized but no deaths have been reported. The issue is strictly limited to specific lots, and other Omnipod 5 products remain safe to use, Insulet said. Shares fell 7%. — CNBC’s Darla Mercado, Christina Cheddar Berk and Lisa Kailai Han contributed reporting.